In a report released today, Emily Bodnar from H.C. Wainwright maintained a Buy rating on Agios Pharma, with a price target of $56.00.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Emily Bodnar has given her Buy rating due to a combination of factors, including Agios Pharma’s consistent commercial execution and progress towards key clinical milestones. The company reported steady commercial performance of Pyrukynd (mitapivat) in PKD, with a slight increase in net revenue, and is preparing for the PDUFA date for thalassemia in December 2025. Despite a delay due to FDA’s request for a REMS submission, the risk-benefit profile of Pyrukynd remains favorable, supporting its approval across all genotypes and levels of transfusion burden.
Additionally, Agios is making strong progress in its ex-US expansion, with a positive CHMP opinion in Europe and approval in Saudi Arabia, which mitigates the US extension delay. The upcoming RISE UP Phase 3 trial results for SCD, expected by the end of 2025, and the potential commercial launch in 2026 further bolster the company’s prospects. The Phase 2b tebapivat trial for LR-MDS is also on track, setting up another key data readout for early 2026. These developments, combined with favorable Phase 2 data for RISE UP, position Agios well for future growth.
In another report released on October 17, Bank of America Securities also maintained a Buy rating on the stock with a $51.00 price target.
Based on the recent corporate insider activity of 42 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of AGIO in relation to earlier this year.